On the other hand, more and more reports seem to suggest the use of target drugs in metastatic disease, suggesting that cetuximab (an epidermal growth factor receptor (EGFR) inhibitor) may be useful in the treatment of advanced cSCC [6,7,8,9,10,11,12,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40]. The gene discussed is EGFR; the disease is metastatic neoplasm.